Skip to main content

Table 1 Clinicopathological characteristics of patients with pancreatic cancer, stratified according to GNRI and PMV

From: The prognostic significance of combined geriatric nutritional risk index and psoas muscle volume in older patients with pancreatic cancer

Characteristics GNRI P PMV P
>  98 (n = 55) ≤ 98 (n = 50) High group (n = 60) Low group (n = 45)
Age, years, median (range) 73.4 (65–84) 75.4 (66–85) 0.057 73.3 (65–85) 76.2 (67–85) 0.013
Sex (male, %) 26 (56.2%) 33 (66.0%) 0.053 29 (48.3%) 30 (66.7%) 0.061
Body mass index, kg/m2, median (range) 22.8 (17.4–30.0) 20.5 (14.0–29.4) <  0.001 22.8 (17.7–30.0) 20.4 (14.0–28.5) <  0.001
Tumor size, mm, median (range) 25.6 (10.0–60.0) 27.5 (4.0–60.0) 0.338 25.7 (13.0–60) 27.6 (4.0–60.0) 0.766
Tumor location (head, %) 25 (45.5%) 32 (64.0) 0.057 33 (55.0%) 24 (53.3%) 0.865
Histological grading (G1, %) 30 (54.5%) 27 (54.0%) 0.955 35 (58.3%) 22 (48.9%) 0.336
Resectability status (BR-PC, %) 2 (3.6%) 0 (0.0%) 0.496 1 (1.7%) 1 (2.2%) 1.000
Lymph node metastasis (present, %) 26 (47.3%) 32 (64.0%) 0.085 34 (56.7%) 24 (53.3%) 0.734
ASA-PS (1 or 2, %) 47 (85.5%) 35 (70%) 0.056 51 (85.0%) 31 (68.9%) 0.048
Preoperative albumin, g/dL, median (range) 4.2 (3.8–4.9) 3.7 (2.1–4.3) <  0.001 4.0 (2.8–4.9) 3.9 (2.1–4.7) 0.033
Preoperative lymphocyte count, median (range) 1495 (140–3800) 1560 (400–6660) 0.947 1512 (140–6660) 1536 (400–3016) 0.763
Preoperative CA19–9, U/mL, median (range) 59.0 (0.7–3221.0) 63.7 (0.7–3270.7) 0.599 59.1 (0.7–3221) 60.8 (0.7–3270.7) 0.591
Neoadjuvant chemotherapy (present, %) 8 (14.5%) 4 (8.0%) 0.366 6 (10.0%) 6 (13.3%) 0.595
Adjuvant chemotherapy (present, %) 32 (60.4%) 27 (55.1%) 0.590 39 (67.2%) 20 (45.5%) 0.027
  1. Abbreviations: G1 Well-differentiated; GNRI Geriatric nutritional risk index; PMV Psoas muscle volume; ASA-PS American Society of Anesthesiologists physical status; CA19–9 Carbohydrate antigen 19–9; BR-PC Borderline resectable pancreatic cancer
\